Tinengotinib is a spectrum-selective multi-kinase inhibitor targeting several oncogenic and immunoregulatory pathways, including FGFR1–3, JAK1/2, VEGFRs, and Aurora A/B kinases. Here the authors report the results of a phase Ib/II trial of tinengotinib as monotherapy or combined with anti-PDL1 atezolizumab in patients with advanced solid tumors.
- Panpan Zhang
- Zuoxing Niu
- Lin Shen
